

ASX Announcement

26 October 2026

Quarterly Activities Report for the Period Ended 30 September 2026

Key Performance Highlights

- Record quarterly sales of \$584k, representing the Company's strongest sales quarter to date
 - Revenue up 774% from the corresponding quarter last year
 - A 176% increase from the previous quarter
 - Quarterly sales exceeded the 2025/26 full year result
 - Monthly sales exceeded \$200,000 for the first time in September
- Secured an up to \$5 million funding facility with RiverFort, including an initial \$1.6 million drawdown
- Partnering with RMIT on a \$499k Australian Government-funded nerve regeneration project
- NervAlign® Nerve Cuff received marketing approval in Indonesia, expanding ReNerve's Asia-Pacific footprint
- Completed first NervAlign® Nerve Cuff cases in Hong Kong and Malaysia, marking initial clinical use in both markets

ReNerve Limited (ASX:RNV, "ReNerve" or "the Company"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("PNI") repair, is pleased to present its Quarterly Report ("Report") for the period ended 30 September 2026 ("Q1 FY27", or the "Quarter"), as well as a financial and corporate update for the period.

ReNerve achieved record quarterly sales of \$584k, delivering its strongest sales quarter to date, including the Company's first month of greater than \$200,000 in sales. The quarter saw very strong sales increases compared to both the corresponding quarter last year and the previous quarter. During the Quarter, the Company also expanded its international commercial footprint, secured additional funding capacity and progressed collaborative research initiatives. Cash at the end of the Quarter was approximately \$1.62 million, following the initial drawdown under the RiverFort funding facility during the period.

"ReNerve has had a very strong quarter which illustrates the benefit of having multiple product ranges in the market. We are also seeing the impact of direct salespeople in the market and working with our 25 distributors across the US as well as the marketing efforts in Asia. We aim to continue to build from these sales increases and this will be aided by additional products coming to market," said ReNerve CEO Dr Julian Chick.



+61 (03) 9482 3940



157 Heidelberg Rd,
Northcote, VIC 3070



www.renerve.com.au

Key milestones included marketing approval for the NervAlign® Nerve Cuff in Indonesia and completion of the first NervAlign® cases in Hong Kong and Malaysia. These developments extended ReNerve's regional presence and demonstrated early clinical adoption in newly entered markets.

ReNerve also entered into a funding facility of up to \$5 million with RiverFort, providing staged access to capital over a three-year availability period to support commercialisation, working capital and general corporate purposes. In addition, ReNerve is partnering with RMIT on a \$499k Australian Government-funded project focused on using a patient's own blood to accelerate nerve regeneration following prostate surgery.

Commercial Updates

Asia-Pacific commercial expansion

During the Quarter, ReNerve advanced its Asia-Pacific commercialisation strategy through regulatory approval in Indonesia and the first clinical use of NervAlign® products in Hong Kong and Malaysia.

In July, ReNerve received marketing approval for its NervAlign® Nerve Cuff in Indonesia. The approval added Southeast Asia's largest economy to ReNerve's growing regional footprint and opened a pathway for the Company to work with local partners to introduce the product to Indonesian clinicians and patients. Indonesia has a population of more than 280 million and a significant clinical need for peripheral nerve repair solutions associated with trauma-related injuries and diabetes.

In September, ReNerve announced the completion of the first NervAlign® Nerve Cuff cases in Hong Kong and Malaysia. The procedures represented the first clinical use of the product in each market and followed the Company's earlier regulatory and distribution progress across the region.

ReNerve partners with RMIT on \$499k nerve regeneration project

In September, ReNerve announced it was partnering with RMIT and Associate Professor Shadi Houshyar on a \$499k project funded by the Commonwealth of Australia through the Department of Education. The project, 'Universal Platform for Tissue Regeneration and Healing: Addressing Nerve Injury', forms part of Australia's Economic Accelerator Ignite Round 2 under the AEA Launch Program.

The collaborative research project is focused on developing a gel using a patient's own blood to accelerate nerve regeneration following prostate surgery. The technology may also have broader application with nerve cuffs, wraps, conduits and the Nerve Guide Matrix. The project remains at the research and development stage and there is no assurance that it will achieve its intended objectives, obtain regulatory approvals or result in a commercial product.

Up to \$5 million RiverFort funding facility secured

In July, ReNerve entered into a convertible note funding facility with RiverFort Global Opportunities PCC Ltd for up to \$5 million. The facility provides staged access to funding over a three-year availability period to support commercialisation, working capital and general corporate purposes.

The initial drawdown had a face value of approximately \$1.6 million and provided approximately \$1.361 million in net cash proceeds after the initial issue discount, drawdown fee and legal costs. The facility is secured by a first-ranking security interest over the Company's present and after-acquired property, including future R&D Tax Incentive proceeds.

Financials

The Company continued to build its sales during the Quarter, achieving record sales of \$584k, up from \$211k in the prior quarter and representing ReNerve's strongest sales quarter to date. Cash receipts from customers increased to \$419k.

During the Quarter, the Company continued to progress its commercialisation and development activities. Research and development expenditure decreased to \$165k from \$752k in the prior quarter, reflecting a lower level of cash expenditure during the period. Product manufacturing and operating activities generated a net cash inflow of \$46k. Other operating expenditure remained broadly consistent with the prior quarter. Net cash used in operating activities was approximately \$1.11 million.

During the Quarter, the Company completed the initial \$1.6 million drawdown under the previously announced funding facility of up to \$5.0 million. The facility provides additional flexibility to support commercialisation, product expansion and market initiatives as ReNerve continues to scale its operations. Transaction costs associated with the funding were \$271k during the Quarter. The Company closed the Quarter with cash and cash equivalents of approximately \$1.62 million.

Corporate

As disclosed in Item 6.1 of the Appendix 4C, ReNerve made aggregate payments to related parties and their associates totalling \$199k during the Quarter. The payments consist of directors' fees, salary and associated payroll costs of non-executive and executive directors.

Comparison to IPO prospectus

Pursuant to Listing Rule 4.7C.2, the table below sets out the Company's expenditure against the use of funds set out in its Prospectus. As at 30 September 2026, the Company has applied the full \$7.0 million allocated under the Prospectus across its strategic objectives and planned activities.

Use of Funds*	Expenditure allocated under prospectus (2-year period)	Actual expenditure to date 30 September 2026**
NervAlign Nerve Conduit Studies	\$1,100,000	\$622,502
Post market study for Nerve Cuff	\$300,000	\$293,644
Nerve Guide Matrix program	\$3,000,000	\$1,182,239
IPO costs	\$900,000	\$967,740
Working capital and operating expenses	\$1,700,000	\$3,933,875
Total Funds Allocated	\$7,000,000	\$7,000,000

* Expenditure allocated under the Prospectus represents the Company's intended use of funds over the two-year period following listing. Actual expenditure reflects the application of those funds across the categories shown above.

** Actual expenditure to date 30 September 2026 per the above table reflects expenditures for the seven quarters ended 30 September 2026, thus including expenditures incurred before the Company's ASX Listing on 26 November 2024.

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

Follow ReNerve:

Website: www.renerve.com.au
LinkedIn: <https://www.linkedin.com/company/renerve-ltd>
InvestorHub: <https://investors.renerve.com.au/>

About ReNerve Limited (ASX:RNV)


ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

For personal use only

Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign® Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

On market

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges** – Three amniotic tissue product ranges used to aid the healing of wounds.

In development

- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.6 billion in 2024 and is projected to reach US\$6.2 billion by 2031.¹

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

For personal use only

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

ReNerve Limited

ABN

23 614 848 216

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	419	419
1.2 Payments for		
(a) research and development	(165)	(165)
(b) product manufacturing and operating costs	46	46
(c) advertising and marketing	(251)	(251)
(d) leased assets	-	-
(e) staff costs	(443)	(443)
(f) administration and corporate costs	(561)	(561)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	14	14
1.5 Interest and other costs of finance paid	(3)	(3)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (movement in trust account)	(166)	(166)
1.9 Net cash from / (used in) operating activities	(1,110)	(1,110)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	(5)	(5)
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(5)	(5)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	1,600	1,600
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(271)	(271)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(50)	(50)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Principal payments of lease liabilities)	(24)	(24)
3.10	Net cash from / (used in) financing activities	1,255	1,255

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,488	1,488
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,110)	(1,110)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(5)	(5)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,255	1,255
4.5	Effect of movement in exchange rates on cash held	(7)	(7)
4.6	Cash and cash equivalents at end of period	1,621	1,621

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	618	469
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (Term Deposits)	1,003	1,019
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,621	1,488

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	199
6.2	Aggregate amount of payments to related parties and their associates included in item 2	
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	5,000	1,600
7.2 Credit standby arrangements		
7.3 Other (please specify)		
7.4 Total financing facilities	5,000	1,600
7.5 Unused financing facilities available at quarter end		3,400
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
<p>The Company has a secured funding facility of up to \$5.0 million with RiverFort Global Opportunities PCC Ltd. At 30 September 2026, \$1.6 million had been drawn. The facility matures 18 months from the date of each drawdown and is secured by a first-ranking security interest over all present and after-acquired property of the Company, including its entitlement to R&D Tax Incentive proceeds. Further drawdowns require mutual agreement and satisfaction of the applicable facility conditions.</p>		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,110)
8.2 Cash and cash equivalents at quarter end (item 4.6)	1,621
8.3 Unused finance facilities available at quarter end (item 7.5)	3,400
8.4 Total available funding (item 8.2 + item 8.3)	5,021
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	4.5
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
<p>Answer:</p>	

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 26 October 2026

Authorised by: By the Board of Directors of ReNerve Limited
 (Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.